Abstract. Although gastric cancer therapy has been improved, more efficient treatment strategies still need to be developed. In the present study, a docetaxel (DOC)-loaded lipid microbubble (DLLD) was prepared and the effect of DLLD combined with ultrasound-triggered microbubble destruction (UTMD) on the growth of a gastric cancer cell line was investigated. The following four groups were included in the present study: Control, DOC, DLLD and DLLD plus UTMD. The determined entrapment efficiency of DLLD is 76±3.5%. The present study demonstrated that treatment with DLLD plus UTMD could significantly inhibit the growth of the cultured gastric cancer cell line BGC-823 via arresting the cell cycle in G2/M phase, inhibiting cell DNA synthesis, promoting cell apoptosis and disrupting mitochondrial membrane potential, as compared with treatment with DOC or DLLD alone. Furthermore, the expression of p53, p21 and Bax were identified to be significantly upregulated, while that of Bcl‑2 was significantly downregulated in the DLLD plus UTMD group. Therefore, treatment with DLLD plus UTMD was more efficient in inhibiting cell proliferation and inducing cell apoptosis in the gastric cancer cell line, when compared with treatment with DOC or DLLD alone, suggesting that DLLD plus UTMD could serve as a promising strategy for the treatment of gastric cancer.

Introduction

Gastric cancer is one of the most common epithelial malignant types of cancer, and is a serious threat to human health (1). Due to specific eating habits, climate and geographical position, China is one of the countries with the highest incidence of gastric cancer (2). Numerous factors have been reported to contribute to the occurrence of gastric cancer, including Helicobacter pylori infection (3), lifestyle (4), socioeconomic status (5), environmental (6) and genetic factors (7-9). For gastric cancer in the early stages of disease, surgical resection is the primary therapeutic strategy, whereas the conventional treatment for advanced gastric cancer is surgical resection combined with chemotherapy (10,11). However, chemotherapy drugs do not only destroy tumor cells, but also attack normal cells, which can result in severe side effects for the patient (12). Therefore, efforts should be made to develop safe tumor-targeting therapeutic strategies.

Previous studies have focused on using ultrasound-triggered microbubble destruction (UTMD) for the treatment of cancer (13,14). Lipid microbubbles, which are widely used as acoustic contrast agents, are also considered to function as good carriers for drug delivery (15-17). The diameter of a nanoscale lipid microbubble is shorter than that of a red blood cell, therefore, it can freely flow with the blood into the pulmonary circulation without blocking it (18). In addition, a nanoscale lipid microbubble can pass through the vascular endothelial cell gap to reach the tissues outside the vessels (18). Drugs loaded lipid microbubbles (DLLMs) can be monitored dynamically by ultrasound (19). Once the microbubbles gather in a tumor-containing organ, relatively low-dose ultrasound was used to irradiate the target organ to destroy the microbubble and release the drugs (19). Following ultrasound irradiation, the loaded drug was rapidly released to the target region to form a relatively high drug concentration (19,20). Therefore, UTMD combined with DLLD may serve as an effective tumor-targeting therapy.

Docetaxel (DOC), a well-known anti-cancer drug, has been demonstrated to be effective for the treatment of
advanced gastric cancer (25-27). In the present study, lipid microbubbles containing DOC were prepared, and the effects of DOC-loaded microbubbles combined with UTMD on the growth of a gastric cell line were investigated.

Materials and methods

Preparation of DLLD. The DOC-loaded lipid microbubble (DLLD) was prepared as previously described (28). Briefly, 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine, Distearoylphosphatidylcholine, Dipalmitoyl phosphatidylethanolamine (all from Sigma-Aldrich, Darmstadt, Germany) and DOC (MedChemExpress, Monmouth Junction, NJ, USA) were mixed to a mass ratio of 1:5:2:2. The mixture was dissolved in chloroform and methanol (1:1, v:v) solution. Following rotary vacuum evaporation, glycerol/PBS (1:9, v:v) was added to form DOC/lipid solution (20 mg/ml). Following perfusion with perfluoropropane gas and mechanical vibration, DLLD was obtained. The unembedded DOC was removed by washing in PBS for 15 min at 4°C. The entrapment efficiency of DLLD was determined by Reverse-Phase High Performance Liquid Chromatography (RP-HPLC; Dalian Elite Analytical Instruments Co., Ltd.). The reverse-phase SinoChrom ODS-BP column (200 x 4.6 mm i.d., pore size 5 µm; Dalian Elite Analytical Instruments Co., Ltd.) was used at a temperature of 30°C. The mobile phase was composed of methanol/acetonitrile/water (50:30:20; v:v) at a flow rate of 1 ml/min. UV absorbance detection was set at 230 nm. The sample quantity was 20 µl. A series of dilutions of DOC (0.1, 0.5, 2.5, 10, 25, 50 and 100 µg/ml) were made to detect the area under the curve, and a linear calibration curve correlating the area under the curve and concentration of DOC was constructed. The concentration of free DOC was calculated according to the linear calibration curve.

Cell culture and treatment. The gastric cancer cell line BGC-823 was purchased from the Shanghai Institute of Cell Biology (Shanghai, China) and maintained in DMEM medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% FBS (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. In the present study, BGC-823 cells were divided into 4 groups: Control, DOC, DLLD and DLLD + UTMD. In the control group, BGC-823 cells were treated with PBS. In the DOC group, BGC-823 cells were treated with 4 µM DOC. In the DLLD group, DLLD (21.3 mg/l) which was equal to 4 µM DOC was used. In the DLLD plus UTMD group, DLLD-treated cells received ultrasound irradiation (0.5 W/cm², 1 MHz) for 30 sec. Cells were treated with PBS, DOC or DLLD for 48 h at 37°C.

Cell viability assay. BGC-823 cells were seeded on a 96-well plate at a density of 3x10⁴ per well and cultured for 24, 48 and 72 h, respectively. A Cell Counting Kit 8 (CCK8; MedChemExpress) was used for cell viability detection. Briefly, cells were incubated with CCK8 (10 µl/well) for 3 h at 37°C. Optical density (OD) was read at 450 nm using a microplate reader. Cell inhibition was calculated according to the formula 1-ODexperimental group/ODcontrol group.

BrdU incorporation assay. A BrdU cell proliferation ELISA kit (Abcam, Cambridge, MA, USA) was used to quantify cells in DNA synthesis. Briefly, cells were incubated with fresh medium containing BrdU solution for 12 h at 37°C. After removing the medium and being washed in PBS for 5 min at room temperature (RT), cells were fixed in 4% paraformaldehyde solution for 10 min at RT and incubated with primary BrdU antibody for 1 h at RT. Cells were subsequently incubated with the secondary antibody for 30 min at RT. Following incubation of cells with TMD and stop solution, the absorbance was determined at 450 nm using a microplate reader (Thermo Fisher Scientific, Inc., USA).

Flow cytometric analysis. Cells in the different experimental groups were digested using 0.25% trypsin and homogenized by pipetting. For cell cycle analysis, cells were centrifuged at 1,000 x g for 5 min at RT and re-suspended in 70% cold ethanol and stored at 4°C overnight. The ethanol was removed by centrifugation (1,000 x g for 5 min at RT) and cells were washed in PBS for 5 min at RT. Cells were then incubated with propidium iodide (PI; Thermo Fisher Scientific, Inc., USA) for 30 min at 4°C in the dark. Immediately following this incubation, the samples were detected using a flow cytometer (Becton-Dickinson, Heidelberg, Germany). The data were analyzed by FlowJo 7.6 software (Stanford University, California, USA).

For cell apoptosis detection, an Annexin V-FITC Apoptosis Detection Kit (Vazyme Biotech, Co., Ltd., Nanjing, China) was used. Following staining with Annexin V and PI for 15 min in the dark, samples were immediately detected using a flow cytometer (Becton, Dickinson and Company). The data were analyzed using FlowJo 7.6.1 software (FlowJo LLC).

For mitochondrial membrane potential (MMP) detection, a JC-1 MMP detection kit (Beyotime Institute of Biotechnology, Haimen, China) was used. Cells treated with carbonyl cyanide 3-chlorophenylhydrazone were set as the positive control. Cells were incubated with JC-1 (5 µg/l) for 1 h at 37°C. The unbound JC-1 was removed by washing in PBS. Samples were immediately detected using a flow cytometer (Becton, Dickinson and Company). The data were analyzed by FlowJo 7.6.1 software (Stanford University, California, USA). When the MMP is high, JC-1 aggregates to form a polymeric compound (red fluorescence) in the matrix of mitochondria. On the contrary, JC-1 cannot aggregate and exists as a JC-1 monomer (green fluorescence) (29). Therefore, the MMP was calculated as the ratio of red fluorescence intensity to green fluorescence intensity.

Western blot analysis. BGC-823 cells were harvested and lysed in RIPA solution (Beyotime Institute of Biotechnology) containing phenylmethanesulfonyl fluoride (PMSF) and phosphatase inhibitor. Following centrifugation (13,000 x g for 15 min at 4°C), the supernatant was collected. The protein content for each sample was determined using the bicinchoninic acid assay method. The protein (25 µg/lane) was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis using a 10% gel. The fractioned proteins in the gel were transferred onto a PVDF membrane. Following immersion in 5% milk/PBST for 1 h at RT, the membrane was incubated with the primary antibodies, including p53 (dilution...
1:500; cat. no. ab26), p21 (dilution 1:1,000; cat. no. ab109520), Bcl-2 (dilution 1:1,000; cat. no. ab32124) and Bax (dilution 1:1,000; cat. no. ab32503; all Abcam) at 4˚C overnight. The unbound primary antibodies in the membranes were removed by washing in PBS for 15 min at RT. The membranes were then incubated with the corresponding HRP-conjugated goat anti-rabbit (dilution 1:3,000; cat. no. ab6721) and goat anti mouse (dilution 1:3,000; cat. no. ab205719; all from Abcam) secondary antibodies at room temperature for 1 h. Protein bands in the membrane were visualized following staining with enhanced chemiluminescence solution.

**Statistical analysis.** Data are expressed as the mean ± SD. One-way ANOVA was used for statistics among groups. When ANOVA was significant, it was followed by a post-hoc Fishers least significant difference test. P<0.05 was considered to indicate a statistically significant difference. The SPSS 19.0 software package was used to perform statistical analyses (IBM Corp.).

**Results**

**Effect of DLLD combined with UTMD on BGC-823 cell growth.** To identify an optimal inhibitory dose of DOC on the growth of BGC-823 cells, BGC-823 cells were treated with serial concentrations of DOC (1, 2, 4 and 8 µM) for 48 h. The results demonstrated that DOC significantly inhibited the growth of BGC-823 in a dose-dependent manner, and the optimum inhibition was observed at a dose of 4 µM (Fig. 1A). As a result, 4 µM DOC was subsequently used in the present study.

Cells were treated with vehicle, DOC, DLLD (capsulation efficiency, 76±3.5%) and DLLD plus UTMD for 0, 24, 48 and 72 h respectively. The results demonstrated that treatment with DLLD plus UTMD significantly inhibited the growth of BGC-823 cells compared with DOC or DLLD treatment alone (Fig. 1B). The inhibitory effect of DOC and DLLD alone were similar (Fig. 1B).

**Effect of DLLD combined with UTMD on BGC-823 cell cycle.** Cell cycle analysis revealed that DOC, DLLD and DLLD plus UTMD could significantly decrease the proportion of cells in the S phase and increase it in the G2/M phase when compared with the control (Fig. 2A). However, treatment with DLLD plus UTMD could further decrease the proportion of cells in the S phase and increase it in the G2/M phase when compared with treatment with DOC or DLLD alone (Fig. 2A). No significant differences were observed between the DOC and DLLD groups (Fig. 2A). This result was further confirmed by analysis of BrdU incorporation and the expression of cell cycle-regulating proteins. Among the four groups, BrdU incorporative cells were the lowest and the expression of p53 and p21 the highest in the DLLD plus UTMD group (Fig. 2B-E).

**Effect of DLLD combined with UTMD on BGC-823 cell apoptosis.** The cell apoptosis assay revealed that DOC, DLLD and DLLD plus UTMD could significantly induce apoptosis in BGC-823 cells when compared with the control (Fig. 3A and B). However, treatment with DLLD plus UTMD could further promote cell apoptosis when compared with treatment with DOC or DLLD alone (Fig. 3A and B). The levels of cell apoptosis in the DOC and DLLD treatment groups were similar (Fig. 3A and B).

**Effect of DLLD combined with UTMD on the MMP of BGC-823 cells.** The results of MMP analysis revealed that treatment with DLLD plus UTMD significantly decreased the MMP level of BGC-823 cells when compared with treatment with DOC or DLLD alone (Fig. 4A). It was also demonstrated that the expression of Bcl-2 was lowest and the expression of Bax highest in the DLLD plus UTMD group (Fig. 4B-D).

**Discussion**

DOC can bind and stabilize intracellular microbubbles, thus disrupting the dynamic balance of microtubule assembly and disassembly, resulting in cell death (30). Due to this property, DOC has been widely used for the treatment of several types of cancer, including gastric cancer (31). However, as a cell cycle inhibitor, DOC is toxic to normal cells, which can result in numerous side effects, including hair loss, neutropenia and anemia (32). Therefore, more tumor-targeting strategies need to be developed. Due to its ability to deliver drugs to the target area, while
minimizing dose and toxicity, DLLD combined with UTMD has attracted attention in the field of solid tumor treatment (33-37). In the present study, the effect of DLLD in combination with UTMD on the growth of a cultured gastric cancer cell line, BGC-823, was investigated. The results demonstrated that combination treatment with DLLD and UTMD exhibited the maximum inhibitory effect on tumor cell growth, primarily by arresting the cell cycle in the G2/M phase, inhibiting cell DNA synthesis, promoting cell apoptosis and disrupting MMP, when compared with treatment with DOC or DLLD alone.

A previous study by Kang et al (35) reported that DLLD combined with UTMD could effectively inhibit the growth...
of VX2 rabbit liver tumors by deferring proliferation and promoting apoptosis. Studies investigating the effect of DLLD combined with UTMD on the growth of other tumors, such as H22 HCC or MHCC-H hepatocellular carcinoma xenografts and prostate carcinoma xenografts, have also demonstrated that DLLD combined with UTMD was the most effective strategy for the inhibition of tumor cell proliferation and the promotion of apoptosis (28,38,39). Consistent with the aforementioned results, the results of the present study indicated that DLLD combined with UTMD could significantly inhibit DNA synthesis, promote cell accumulation in the G2/M phase and stimulate cell apoptosis.

The underlying molecular mechanism of DOC-induced cell cycle arrest and apoptosis may be associated with the high expression of p53, a well-characterized molecule that mediates cell cycle arrest and cell apoptosis (40). An increasing amount of evidence has suggested that p53 serves a critical role in sensitizing tumor cells to DOC. A previous study demonstrated that activating p53 sensitized colorectal cancer to treatment with DOC (41). Another study demonstrated that the p53 pathway was responsible for mediating tumor cell cycle arrest and cell apoptosis in response to combination treatment with DLLD and resveratrol (42). In addition, a recent clinical study demonstrated that the nanocomplex carrying the p53 gene in combination with DOC could significantly block solid tumor development (43). The present study identified that DLLD combined with UTMD induced the highest expression level of p53 and its downstream effector, p21, in the BGC-823 cell line. Therefore, it was concluded that the tumor-destroying effect of DLLD combined with UTMD was at least partly mediated by promoting the expression of p53.

It has previously been reported that ultrasound combined with microbubbles induces cavitation, resulting in mitochondrial damage and subsequently mitochondria-dependent cell apoptosis (44,45). Cavitation is associated with inducing the opening of the mitochondrial permeability transition pore (44). The present study found that DLLD combined with UTMD could significantly lower MMP levels of BGC-823 cells. Furthermore, the expression of Bcl-2 (anti-apoptotic factor) was significantly inhibited and Bax (which is pro-apoptotic factor) was significantly promoted, following combination treatment with DLLD and UTMD. Bcl-2 and Bax are mitochondrial membrane proteins, and the ratio of Bcl-2 to Bax determines whether cells undergo apoptosis (46). A previous study using DOC-loaded human serum albumin nanoparticles for the treatment of breast cancer cells observed that the nanoparticles could significantly increase the expression of Bax, thereby elevating the ratio of Bax to Bcl-2, leading to cell apoptosis (47). A different study has also demonstrated that taxotere could abrogate the pro-apoptotic function of Bcl-2 (48). Therefore, we speculate that the cavitation-induced instability of the mitochondrial membrane by UTMD may be further enhanced by DOC, resulting in strong cell apoptosis.

In conclusion, the results of the present study demonstrated that combination treatment with DLLD and UTMD could more effectively inhibit the growth of a gastric cell line, through cell

Figure 4. Effect of DLLD combined with UTMD on the MMP of BGC-823 cells. Cells were treated with PBS, DOC, DLLD or DLLD plus UTMD for 48 h. (A) MMP assay by staining with JC-1. (B) Western blot analysis of Bcl-2 and Bax expression. Quantified protein levels of (C) Bax and (D) Bcl-2. Values are presented as the mean ± SD (n=5 for each group). *P<0.05 and **P<0.01 vs. Control. *P<0.05 and ***P<0.001 vs. DOC. &&P<0.01 and &&&P<0.001 vs. DLLD. DOC, docetaxel; DLLD, DOC-loaded lipid microbubble; UTMD, ultrasound-triggered microbubble destruction; MMP, mitochondrial membrane potential.
cycle arrest, promotion of apoptosis and disruption of MMP, when compared with treatment with DOC or DLLD alone. To the best of our knowledge, this is the first study that focused on investigating the effect of combination treatment with DLLD and UTMD on the growth of a gastric cancer cell line. The findings suggested that DLLD plus UTMD could be a promising novel strategy for the treatment of gastric cancer.

Acknowledgements

Not applicable.

Funding

This project was supported by the Key Research and Development Plan from the Jiangxi Provincial Science and Technology Department (grant no. 2017BBG70062).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

JWW conceived and designed this study. BL, PZ, HLL and LH performed all of the experiments and data analysis. BL and PZ wrote the manuscript. JWW reviewed the manuscript. All the authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References